Jerusalem, 20 July, 2025 (TPS-IL) — NLS Pharmaceutics announced continued progress in iTOL-102, a potential cure for Type 1 diabetes developed jointly by Israel’s Kadimastem and U.S.-based iTolerance. The Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation approved a new milestone payment of NIS 564,400 ($166,000), bringing its total investment in the Israeli-American collaboration to nearly NIS 3 million ($882,000).
iTOL-102 combines Kadimastem’s IsletRx stem-cell technology with iTolerance’s immunomodulatory platform to offer insulin production without lifelong immunosuppression. The companies are preparing for human clinical trials following a successful pre-IND meeting with the U.S. FDA, marking a significant step for Israeli biotech in the global fight against diabetes.